3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors

Bioorg Med Chem Lett. 2003 Apr 17;13(8):1403-8. doi: 10.1016/s0960-894x(03)00172-0.

Abstract

Cyclic nucleotide phosphodiesterase IV (PDE IV) inhibitors find utility in asthma and Chronic Obstructive Pulmonary Disease (COPD) therapy. A series of 29 thieno[3,2-d]pyrimidines with affinity for PDE IV was subjected to three dimensional quantitative structure activity relationship (3D-QSAR) studies using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). Both CoMFA and CoMSIA provided statistically valid models with good correlative and predictive power. The incorporation of hydrophobic, hydrogen bond donor and hydrogen bond acceptor fields showed insignificant improvement in CoMSIA model. The 3D-QSAR models provide information for predicting the affinity of related compounds and designing more potent inhibitors.

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology*
  • Hydrocarbons, Cyclic / chemistry
  • Hydrocarbons, Cyclic / pharmacology
  • Hydrogen Bonding
  • Hydrophobic and Hydrophilic Interactions
  • Inhibitory Concentration 50
  • Models, Molecular
  • Pyrimidines / chemistry*
  • Pyrimidines / pharmacology*
  • Quantitative Structure-Activity Relationship
  • Static Electricity
  • Thermodynamics

Substances

  • Enzyme Inhibitors
  • Hydrocarbons, Cyclic
  • Pyrimidines
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 4